Clinical trialPhase 1Terminated
Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer
- Outcome
- Stopped earlyCompany manufacturing study drug was unable to continue production. (Business decision)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- February 2009
- Expected end
- September 2012
- Enrollment
- 18 participants
- Sites
- 1
- Primary outcomes
- To evaluate the safety and tolerability of repeated IMP321 subcutaneous injections in patients being treated with gemcitabine for advanced pancreas cancer.; To determine the dose limiting toxicities of IMP321 in patients being treated with gemcitabine for advanced pancreas cancer.
- Sponsor
- Other
- Results posted
- No
- Last update
- 12 June 2013
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try